Dry Age-Related Macular Degeneration

SEATTLE — In the U.S. and Canada, the burden of geographic atrophy on patients and caregivers is “substantial and multifaceted,” according to a study presented at the American Society of Retina Specialists annual meeting.

In this video, Manjot K. Gill, MD, professor of ophthalmology and medical education at Northwestern Feinberg School of Medicine, discusses how treatment approaches differ when treating wet AMD and dry AMD.

Adults with late age-related macular degeneration may experience greater visual and physical difficulties compared with adults without AMD, according to study results published in Translational Vision Science and Technology.

Bausch Health has entered into an agreement with Allegro Ophthalmics to acquire an option to purchase all of Allegro’s ophthalmology assets, according to a press release.

A patient enrolled in a phase 1/2a study of OpRegen for dry age-related macular degeneration showed signs of retinal tissue regeneration, according to a press release.

Subretinal transplantation of retinal pigment epithelial cells derived from human embryonic stem cells appears to be well tolerated in patients with dry age-related macular degeneration and geographic atrophy, according to the interim results of a phase 1/2 clinical trial.

Social distancing, reducing our clinical volume and canceling elective surgeries have led nationally and in Ohio to a significant flattening of our curve. Locally we are currently trending at a model of social distancing between 60% and 80% and have blunted the curve such that our health care organization can now get back to elective patients while not being overwhelmed with COVID-19 inpatients.

The FDA has granted fast track designation to Zimura for the treatment of geographic atrophy secondary to dry age-related macular degeneration, Iveric bio announced in a press release.

Iveric bio will delay enrollment in its second pivotal clinical trial for Zimura due to the coronavirus global pandemic, the company announced in a press release.

LumiThera is expanding research of its photobiomodulation platform, the Valeda light delivery system, with new studies evaluating its use in patients with diabetic retinopathy, the company announced in a press release.